Global Lifestyle Drugs

Lifestyle Drugs Comprehensive Study by Type (Depression, Dermatology, Sexual dysfunction, Obesity), Application (Children, Adults, Senior Citizens), Form (Tablets, External Use, Injection) Players and Region - Global Market Outlook to 2030

Lifestyle Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Lifestyle Drugs Market Scope
Lifestyle drug is basically an imprecise term which is been commonly applied to the medications which treat the non–life-threatening and some of the non-painful conditions such as baldness, erectile dysfunction, wrinkles, or acne, that the speaker perceives as minor conditions of medical relative to others or as either not medical problems at all. This is sometimes intended as a pejorative, bearing the implication which the scarce medical research resources have been allocated to develop such drugs. A large number of lifestyle drugs have been approved by the FDA and other regulatory bodies of different countries for some skin conditions and disorders related to lifestyle. Some of the indications such as pigmentation, acne, wrinkles, psoriasis and many others can be treated by such drugs.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledALLERGAN PLC (Ireland), BMS (United States), Eli Lilly (United States), Pfizer (United States), Acerus Pharmaceuticals (Canada), Alkermes (Ireland), Amorepacific (South Korea), AndroScience (Slovakia), AstraZeneca (United Kingdom) and Avanir Pharmaceuticals (United States)
CAGR%


Despite the presence of competition and brand effect problems, due to the awareness of end-users and their demand for high-end products, investors are still optimistic about this area. There will be more new investors entering into this industry in the future. The manufacturers who want to occupy the market must depend on market mechanism reform, manufacturing equipment innovation, core technology improvement, and brand establishment. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Lifestyle Drugs market throughout the predicted period.

ALLERGAN PLC (Ireland), BMS (United States), Eli Lilly (United States), Pfizer (United States), Acerus Pharmaceuticals (Canada), Alkermes (Ireland), Amorepacific (South Korea), AndroScience (Slovakia), AstraZeneca (United Kingdom) and Avanir Pharmaceuticals (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research are Celtaxsys (Georgia), Cerecor (United States), Corcept Therapeutics (United States) and Cosmo Pharmaceuticals (Ireland).

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.

Segmentation Overview
The study have segmented the market of Global Lifestyle Drugs market by Type , by Application (Children, Adults and Senior Citizens) and Region with country level break-up.

On the basis of geography, the market of Lifestyle Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). region held largest market share in the year 2023.

Market Leaders and their expansionary development strategies
In March 2024, Cipla has compled its USD 550-million acquisition of US generic drug makers InvaGen and Exelan. This gives the 80-year-old Indian drug maker a bigger presence in the lucrative US market. This is its second major acquisition after the Rs 2,700-crore deal to buy South African drug firm Medpro in 2013.
In November 2023, Nordisk is pushing ahead with the launches of weight-loss drug Wegovy in Europe and Japan, even as it struggles to keep up with demand. The Danish drugmak is working to convince European governments and insurers to reimburse the drug seeking to position it as more than a lifestyle drug.
“The Food and Drug Administration (FDA), a regulatory agency within the Department of Health and Human Services, regulates the safety and effectiveness of drugs sold in the United States. FDA divides that responsibility into two phases. In the preapproval (premarket) phase, FDA reviews manufacturers’ applications to market drugs in the United States; a drug may not be sold unless it has FDA approval. Once a drug is on the market, FDA continues its oversight of drug safety and effectiveness. That postapproval (postmarket) phase lasts as long as the drug is on the market.”

Influencing Trend:
High Demand for Quick Diagnosis and Rising Expenditure on Personal Care

Market Growth Drivers:
Increasing Skin Related Infection, Growing Demand for Topical Dermatological Drugs and Changing Lifestyle Standard Fueled By Rising in Disposable Income

Challenges:
Lack of Awareness in the Emerging Economies

Restraints:
Stringent Government Regulations Regarding Drugs and Threat of Side Effects Associated With Lifestyle Drugs

Opportunities:
Development of Innovative Products, Increasing Demand for Lifestyle Drugs for Proper Lifestyle and Growing Healthcare Infratstrure in the Developing Economies

Key Target Audience
Lifestyle Drugs Manufacturers, Traders and Distributors of Lifestyle Drugs, Research and Development Institutes, Potential Investors, Nationalized Laboratory, Government and Research Organizations, Trade Associations and Industry Bodies, Commercial Research & Development Institutions and Others

Report Objectives / Segmentation Covered

By Type
  • Depression
  • Dermatology
  • Sexual dysfunction
  • Obesity
By Application
  • Children
  • Adults
  • Senior Citizens
By Form
  • Tablets
  • External Use
  • Injection

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Skin Related Infection
      • 3.2.2. Growing Demand for Topical Dermatological Drugs
      • 3.2.3. Changing Lifestyle Standard Fueled By Rising in Disposable Income
    • 3.3. Market Challenges
      • 3.3.1. Lack of Awareness in the Emerging Economies
    • 3.4. Market Trends
      • 3.4.1. High Demand for Quick Diagnosis
      • 3.4.2. Rising Expenditure on Personal Care
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Lifestyle Drugs, by Type, Application, Form and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Lifestyle Drugs (Value)
      • 5.2.1. Global Lifestyle Drugs by: Type (Value)
        • 5.2.1.1. Depression
        • 5.2.1.2. Dermatology
        • 5.2.1.3. Sexual dysfunction
        • 5.2.1.4. Obesity
      • 5.2.2. Global Lifestyle Drugs by: Application (Value)
        • 5.2.2.1. Children
        • 5.2.2.2. Adults
        • 5.2.2.3. Senior Citizens
      • 5.2.3. Global Lifestyle Drugs by: Form (Value)
        • 5.2.3.1. Tablets
        • 5.2.3.2. External Use
        • 5.2.3.3. Injection
      • 5.2.4. Global Lifestyle Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Lifestyle Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. ALLERGAN PLC (Ireland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. BMS (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Acerus Pharmaceuticals (Canada)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Alkermes (Ireland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Amorepacific (South Korea)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. AndroScience (Slovakia)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. AstraZeneca (United Kingdom)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Avanir Pharmaceuticals (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Lifestyle Drugs Sale, by Type, Application, Form and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Lifestyle Drugs (Value)
      • 7.2.1. Global Lifestyle Drugs by: Type (Value)
        • 7.2.1.1. Depression
        • 7.2.1.2. Dermatology
        • 7.2.1.3. Sexual dysfunction
        • 7.2.1.4. Obesity
      • 7.2.2. Global Lifestyle Drugs by: Application (Value)
        • 7.2.2.1. Children
        • 7.2.2.2. Adults
        • 7.2.2.3. Senior Citizens
      • 7.2.3. Global Lifestyle Drugs by: Form (Value)
        • 7.2.3.1. Tablets
        • 7.2.3.2. External Use
        • 7.2.3.3. Injection
      • 7.2.4. Global Lifestyle Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Lifestyle Drugs: by Type(USD Million)
  • Table 2. Lifestyle Drugs Depression , by Region USD Million (2018-2023)
  • Table 3. Lifestyle Drugs Dermatology , by Region USD Million (2018-2023)
  • Table 4. Lifestyle Drugs Sexual dysfunction , by Region USD Million (2018-2023)
  • Table 5. Lifestyle Drugs Obesity , by Region USD Million (2018-2023)
  • Table 6. Lifestyle Drugs: by Application(USD Million)
  • Table 7. Lifestyle Drugs Children , by Region USD Million (2018-2023)
  • Table 8. Lifestyle Drugs Adults , by Region USD Million (2018-2023)
  • Table 9. Lifestyle Drugs Senior Citizens , by Region USD Million (2018-2023)
  • Table 10. Lifestyle Drugs: by Form(USD Million)
  • Table 11. Lifestyle Drugs Tablets , by Region USD Million (2018-2023)
  • Table 12. Lifestyle Drugs External Use , by Region USD Million (2018-2023)
  • Table 13. Lifestyle Drugs Injection , by Region USD Million (2018-2023)
  • Table 14. South America Lifestyle Drugs, by Country USD Million (2018-2023)
  • Table 15. South America Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 16. South America Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 17. South America Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 18. Brazil Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 19. Brazil Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 20. Brazil Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 21. Argentina Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 22. Argentina Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 23. Argentina Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 24. Rest of South America Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 25. Rest of South America Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 26. Rest of South America Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 27. Asia Pacific Lifestyle Drugs, by Country USD Million (2018-2023)
  • Table 28. Asia Pacific Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 29. Asia Pacific Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 30. Asia Pacific Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 31. China Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 32. China Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 33. China Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 34. Japan Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 35. Japan Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 36. Japan Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 37. India Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 38. India Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 39. India Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 40. South Korea Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 41. South Korea Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 42. South Korea Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 43. Taiwan Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 44. Taiwan Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 45. Taiwan Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 46. Australia Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 47. Australia Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 48. Australia Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 49. Rest of Asia-Pacific Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 50. Rest of Asia-Pacific Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 51. Rest of Asia-Pacific Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 52. Europe Lifestyle Drugs, by Country USD Million (2018-2023)
  • Table 53. Europe Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 54. Europe Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 55. Europe Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 56. Germany Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 57. Germany Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 58. Germany Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 59. France Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 60. France Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 61. France Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 62. Italy Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 63. Italy Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 64. Italy Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 65. United Kingdom Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 66. United Kingdom Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 67. United Kingdom Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 68. Netherlands Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 69. Netherlands Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 70. Netherlands Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 71. Rest of Europe Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 72. Rest of Europe Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 73. Rest of Europe Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 74. MEA Lifestyle Drugs, by Country USD Million (2018-2023)
  • Table 75. MEA Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 76. MEA Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 77. MEA Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 78. Middle East Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 79. Middle East Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 80. Middle East Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 81. Africa Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 82. Africa Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 83. Africa Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 84. North America Lifestyle Drugs, by Country USD Million (2018-2023)
  • Table 85. North America Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 86. North America Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 87. North America Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 88. United States Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 89. United States Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 90. United States Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 91. Canada Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 92. Canada Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 93. Canada Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 94. Mexico Lifestyle Drugs, by Type USD Million (2018-2023)
  • Table 95. Mexico Lifestyle Drugs, by Application USD Million (2018-2023)
  • Table 96. Mexico Lifestyle Drugs, by Form USD Million (2018-2023)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Lifestyle Drugs: by Type(USD Million)
  • Table 108. Lifestyle Drugs Depression , by Region USD Million (2025-2030)
  • Table 109. Lifestyle Drugs Dermatology , by Region USD Million (2025-2030)
  • Table 110. Lifestyle Drugs Sexual dysfunction , by Region USD Million (2025-2030)
  • Table 111. Lifestyle Drugs Obesity , by Region USD Million (2025-2030)
  • Table 112. Lifestyle Drugs: by Application(USD Million)
  • Table 113. Lifestyle Drugs Children , by Region USD Million (2025-2030)
  • Table 114. Lifestyle Drugs Adults , by Region USD Million (2025-2030)
  • Table 115. Lifestyle Drugs Senior Citizens , by Region USD Million (2025-2030)
  • Table 116. Lifestyle Drugs: by Form(USD Million)
  • Table 117. Lifestyle Drugs Tablets , by Region USD Million (2025-2030)
  • Table 118. Lifestyle Drugs External Use , by Region USD Million (2025-2030)
  • Table 119. Lifestyle Drugs Injection , by Region USD Million (2025-2030)
  • Table 120. South America Lifestyle Drugs, by Country USD Million (2025-2030)
  • Table 121. South America Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 122. South America Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 123. South America Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 124. Brazil Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 125. Brazil Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 126. Brazil Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 127. Argentina Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 128. Argentina Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 129. Argentina Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 130. Rest of South America Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 131. Rest of South America Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 132. Rest of South America Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 133. Asia Pacific Lifestyle Drugs, by Country USD Million (2025-2030)
  • Table 134. Asia Pacific Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 135. Asia Pacific Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 136. Asia Pacific Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 137. China Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 138. China Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 139. China Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 140. Japan Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 141. Japan Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 142. Japan Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 143. India Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 144. India Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 145. India Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 146. South Korea Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 147. South Korea Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 148. South Korea Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 149. Taiwan Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 150. Taiwan Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 151. Taiwan Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 152. Australia Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 153. Australia Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 154. Australia Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 155. Rest of Asia-Pacific Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 156. Rest of Asia-Pacific Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 157. Rest of Asia-Pacific Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 158. Europe Lifestyle Drugs, by Country USD Million (2025-2030)
  • Table 159. Europe Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 160. Europe Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 161. Europe Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 162. Germany Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 163. Germany Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 164. Germany Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 165. France Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 166. France Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 167. France Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 168. Italy Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 169. Italy Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 170. Italy Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 171. United Kingdom Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 172. United Kingdom Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 173. United Kingdom Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 174. Netherlands Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 175. Netherlands Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 176. Netherlands Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 177. Rest of Europe Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 178. Rest of Europe Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 179. Rest of Europe Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 180. MEA Lifestyle Drugs, by Country USD Million (2025-2030)
  • Table 181. MEA Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 182. MEA Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 183. MEA Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 184. Middle East Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 185. Middle East Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 186. Middle East Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 187. Africa Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 188. Africa Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 189. Africa Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 190. North America Lifestyle Drugs, by Country USD Million (2025-2030)
  • Table 191. North America Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 192. North America Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 193. North America Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 194. United States Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 195. United States Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 196. United States Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 197. Canada Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 198. Canada Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 199. Canada Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 200. Mexico Lifestyle Drugs, by Type USD Million (2025-2030)
  • Table 201. Mexico Lifestyle Drugs, by Application USD Million (2025-2030)
  • Table 202. Mexico Lifestyle Drugs, by Form USD Million (2025-2030)
  • Table 203. Research Programs/Design for This Report
  • Table 204. Key Data Information from Secondary Sources
  • Table 205. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Lifestyle Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Lifestyle Drugs: by Application USD Million (2018-2023)
  • Figure 6. Global Lifestyle Drugs: by Form USD Million (2018-2023)
  • Figure 7. South America Lifestyle Drugs Share (%), by Country
  • Figure 8. Asia Pacific Lifestyle Drugs Share (%), by Country
  • Figure 9. Europe Lifestyle Drugs Share (%), by Country
  • Figure 10. MEA Lifestyle Drugs Share (%), by Country
  • Figure 11. North America Lifestyle Drugs Share (%), by Country
  • Figure 12. Global Lifestyle Drugs share by Players 2023 (%)
  • Figure 13. Global Lifestyle Drugs share by Players (Top 3) 2023(%)
  • Figure 14. Global Lifestyle Drugs share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. ALLERGAN PLC (Ireland) Revenue, Net Income and Gross profit
  • Figure 17. ALLERGAN PLC (Ireland) Revenue: by Geography 2023
  • Figure 18. BMS (United States) Revenue, Net Income and Gross profit
  • Figure 19. BMS (United States) Revenue: by Geography 2023
  • Figure 20. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 21. Eli Lilly (United States) Revenue: by Geography 2023
  • Figure 22. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 23. Pfizer (United States) Revenue: by Geography 2023
  • Figure 24. Acerus Pharmaceuticals (Canada) Revenue, Net Income and Gross profit
  • Figure 25. Acerus Pharmaceuticals (Canada) Revenue: by Geography 2023
  • Figure 26. Alkermes (Ireland) Revenue, Net Income and Gross profit
  • Figure 27. Alkermes (Ireland) Revenue: by Geography 2023
  • Figure 28. Amorepacific (South Korea) Revenue, Net Income and Gross profit
  • Figure 29. Amorepacific (South Korea) Revenue: by Geography 2023
  • Figure 30. AndroScience (Slovakia) Revenue, Net Income and Gross profit
  • Figure 31. AndroScience (Slovakia) Revenue: by Geography 2023
  • Figure 32. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 33. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 34. Avanir Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 35. Avanir Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 36. Global Lifestyle Drugs: by Type USD Million (2025-2030)
  • Figure 37. Global Lifestyle Drugs: by Application USD Million (2025-2030)
  • Figure 38. Global Lifestyle Drugs: by Form USD Million (2025-2030)
  • Figure 39. South America Lifestyle Drugs Share (%), by Country
  • Figure 40. Asia Pacific Lifestyle Drugs Share (%), by Country
  • Figure 41. Europe Lifestyle Drugs Share (%), by Country
  • Figure 42. MEA Lifestyle Drugs Share (%), by Country
  • Figure 43. North America Lifestyle Drugs Share (%), by Country
List of companies from research coverage that are profiled in the study
  • ALLERGAN PLC (Ireland)
  • BMS (United States)
  • Eli Lilly (United States)
  • Pfizer (United States)
  • Acerus Pharmaceuticals (Canada)
  • Alkermes (Ireland)
  • Amorepacific (South Korea)
  • AndroScience (Slovakia)
  • AstraZeneca (United Kingdom)
  • Avanir Pharmaceuticals (United States)
Additional players considered in the study are as follows:
Celtaxsys (Georgia) , Cerecor (United States) , Corcept Therapeutics (United States) , Cosmo Pharmaceuticals (Ireland)
Select User Access Type

Key Highlights of Report


Mar 2024 218 Pages 90 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Lifestyle Drugs Quantitative research analysis
Global Lifestyle Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The key segments that are playing vital role in Lifestyle Drugs Market are by type [Depression, Dermatology, Sexual dysfunction and Obesity], by end use application [Children, Adults and Senior Citizens].
The Lifestyle Drugs Market is gaining popularity and expected to see strong valuation by 2030.
  • Increasing Skin Related Infection
  • Growing Demand for Topical Dermatological Drugs
  • Changing Lifestyle Standard Fueled By Rising in Disposable Income

Know More About Global Lifestyle Drugs Report?

Have a Query? Click Here

Other Related Reports

Cattle Health Comprehensive Study by Type (Vaccines, Pharmaceuticals (Parasiticides, Anti-infective, Anti-inflammatory, Analgesics, Others), Feed Additives (Nutritional, Medicinal ), Diagnostics), Ap...
$ 3650
Wound Dressing Comprehensive Study by Type (Advanced Wound Dressings, Traditional Wound Dressing), Application (Diabetic Foot Ulcers, Pressure Ulcers, Venous Ulcers, Surgical Wounds, Burns, Others), ...
$ 3750
Medical Scrub Caps Comprehensive Study by Type (Bouffant Scrub Cap, Integral, Close-Fitting, Others), Application (Operating Room, Clean Room, Pharmaceutical, Laboratory), Distribution Channel (Onlin...
$ 3650
Medical Air Conditioners Comprehensive Study by Application (Pharmacies, Clinics, Hospitals, Veterinary, Others), Mounting (Wall-Mounted, Ceiling-Mounted), Air Conditioner (Central Air Conditioning, ...
$ 3450
Home Health Care Providers Comprehensive Study by Type (Home Telehealth Monitoring Devices, Home Telehealth Services, Telehealth Software Solutions), Product (Testing, Screening, and Monitoring (Bloo...
$ 3750
Kidney Dialysis Centers Comprehensive Study by Type (Peritoneal Dialysis, Home Hemodialysis, In-Center Hemodialysis, Others), Application (Health Care Research Centre, Government Hospitals, Private H...
$ 3350